MUMBAI: India's pharmaceutical industry is scrambling to assess the impact of proposed tariffs on generic drugs announced by United States President Donald Trump. Drugs and pharmaceutical products accounted for about 5.8 per cent of India’s total goods exports last year. Trump announced on Tuesday (Jul 21) that imported generic medicines will continue to enter the US tariff-free for two years, giving manufacturers time to shift production to America. “This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them,” Trump said in a social media post. HIGH STAKES FOR INDIA'S DRUG EXPORTERSMore than 90 per cent of prescriptions filled in the US are generic medicines, according to the Food and Drug Administration.